Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Nov
07
Today In Oncology
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
Armando Giuliano Honored With 2025 William L. McGuire Memorial Lecture Award
Hepatic Arterial Infusion Pump Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma
Physician-Complementing Artificial Intelligence in Oncology
First-Line Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo